Genetically proxied inhibition of HMGCR provided evidence of a similar magnitude of effect on overall prostate cancer as PCSK9, although the 95% CI included the null (OR = 0.83, 95% CI = 0.62 to 1.13, P = 0.244). This evidence concerns the gene PCSK9 and prostate cancer.